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sites on Alzheimer’s amyloid-b aggregates
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Mark R. Wilson2, Samuel I. A. Cohen1, Sara Linse3, Michele Vendruscolo1,
Christopher M. Dobson1, Tuomas P. J. Knowles1,4*, Paolo Arosio1,5*
The aggregates of theAb peptide associatedwith Alzheimer’s disease are able to both grow in size aswell as generate,
through secondary nucleation, new small oligomeric species, that are major cytotoxins associated with neuronal
death. Despite the importance of these amyloid fibril-dependent processes, their structural and molecular underpin-
nings have remained challenging to elucidate. Here, we consider two molecular chaperones: the Brichos domain,
which suppresses specifically secondary nucleation processes, and clusterin which our results show is capable of
inhibiting, specifically, the elongation of Ab fibrils at remarkably low substoichiometric ratios. Microfluidic diffusional
sizing measurements demonstrate that this inhibition originates from interactions of clusterin with fibril ends with
high affinity. Kinetic experiments in the presence of both molecular chaperones reveal that their inhibitory effects
are additive and noncooperative, thereby indicating that the reactive sites associated with the formation of new ag-
gregates and the growth of existing aggregates are distinct.INTRODUCTION
A large number of observations, including genetic and epidemiologi-
cal studies, indicate that the aberrant aggregation of normally soluble
peptides and proteins into insoluble amyloid fibrils is associated with
the onset and the progression of a wide range of neurodegenerative
disorders (1–6). Biophysical studies are currently revealing important
molecular details underlying the formation of the fibrillar aggregates
from initially supersaturated monomer solutions (7–9). From these
studies, a picture is emerging in which the aggregation process is seen
to be the result of a complex cascade of individualmicroscopic steps of
nucleation and growth (10). Secondary nucleation, in particular, in-
creases the rate of formation of low–molecular weight oligomers that
accompany the formation of mature fibrils and are currently thought
to represent the most toxic species (3, 10–13). Inhibition of these key
aggregation processes therefore represents a potentially attractive ther-
apeutic opportunity in the search for strategies to combat amyloid-
associated diseases (14).
Understanding themolecular determinants of these differentmech-
anistic processes is therefore of fundamental importance to design
strategies that target specifically the reactions responsible for the for-
mation of the most highly toxic species. In the context of developing
drugs to combat protein aggregation disorders, targeted interventions,
rather than nonspecific suppression of the aggregation process, are
required (14). The inhibition of different microscopic steps can lead
to similar effects on the overall formation of amyloid fibrils, yet can
havemarked differences in the generation of toxic oligomeric species
(14–16). An intervention strategy targeting the specific microscopic
steps that represent the major sources of the formation of these oligo-
mers is, therefore, likely to be an optimal approach to suppress the
most detrimental effects of protein aggregation.Recent developments in the analysis of kinetic profiles of aggre-
gation reactions represent a powerful tool in the analysis of the com-
plexmechanistic details at themolecular level, generating information
from experimental measurements that is not otherwise achievable
(9, 17). An important consequence of these advances is the ability to
investigate the ways in which nature suppresses amyloid formation
in normally functioning organisms by analyzing the mechanism of
action of molecular chaperones (18). These species are key compo-
nents of the protein homeostasis network whose mode of action
ranges from assisting protein folding following biosynthesis to facil-
itating the degradation of these systems that have failed to fold or to
remain completely folded (19, 20). By investigating a series of molec-
ular chaperones that can inhibit selectively one or more specific steps
in the aggregation process of different amyloidogenic proteins, we
have shown that these vital molecules can influence aggregation pro-
cesses through a variety of different microscopic events and reveal
the complex mechanism that nature has evolved to maintain protein
homoeostasis (18, 21, 22). With this information, we can exploit mo-
lecular chaperones to perturb, in a selective way, a given aggregation
network and thereby investigate the effects of individual steps in the
reaction on the formation of key intermediate species. For example, a
molecular chaperone belonging to theBrichos family (proSP-CBrichos)
has been shown to inhibit the aggregation of Ab42, a 42-residue pro-
tein fragment of the amyloid-b peptide that is the most abundant
isoform in amyloid deposits closely associated with Alzheimer’s dis-
ease (AD), by suppressing specifically the secondary nucleation re-
action and resulting in a marked reduction in the generation of toxic
oligomeric species (11).
In the present study, we have built on this approach to reveal the
effects of two well-characterized molecular chaperones on different
microscopic steps of the aggregation of Ab(M1-42). In particular, we
first investigate the inhibitory mechanism of clusterin. Clusterin is
an important member of a family of largely extracellular chaperones,
which have been observed to interact with different aggregation states
of amyloidogenic proteins, including oligomers, prefibrillar species,
and mature fibrils, and hence to affect events leading to the formation
of amyloid fibrils (23–28). In particular, experiments with synthetic
Ab40 and Ab42 have shown that clusterin can bind to oligomers1 of 9
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Ab(M1-42) demonstrate that clusterin is highly effective in retarding
the aggregation process of Ab(M1-42) at low substoichiometric ratios
and physiological concentrations by inhibiting specifically the elonga-
tion process (23, 26, 27, 29). We then examine the combined ability of
clusterin and another type of molecular chaperone, a Brichos domain,
to influence specificmicroscopic events in the aggregation process and
analyze the cooperative nature of the inhibition process to extract
information about the location of specific sites on the fibrils that are
involved with secondary nucleation and fibril elongation.RESULTS
Clusterin suppresses specifically the elongation step
of Ab(M1-42) aggregation
To investigate the capability of clusterin to inhibit the aggregation
process of Ab(M1-42), we first incubated the peptide in the absence
and presence of different concentrations of the molecular chaperone
andmonitored the time evolution of fibril formation by recording the
fluorescence signal of the dye thioflavin T (ThT), which is strongly
enhanced by its interaction with amyloid structures (Fig. 1). We ob-
served a delay in the fibril formation process that is proportional to
the concentration of clusterin present in the system even at very low
substoichiometric molar ratios (including 1:500) of clusterin. We
then carried out a series of kinetic experiments at different concentra-
tions of Ab(M1-42) (see fig. S1) to explore the dependence of the var-
ious microscopic steps in the aggregation cascade and the presence of
themolecular chaperone bymeans of kinetic analysis (14). According
to this strategy, the experimental kinetic profiles determined at a
range of Ab(M1-42) concentrations are compared to simulations in
which individual events are specifically suppressed (Fig. 1, A to C).
The least-squares error function, defined in Materials and Methods,
at a clusterin concentration of 135 nM is 1.5, 0.2, and 1.5 for the spe-
cific inhibition of kn, k+, and k2, respectively. This comparison suggests
that clusterin inhibits the overall aggregation process by suppressing
specifically the rate of elongation of the Ab(M1-42) fibrils while hav-
ing no detectable effect on primary and secondary nucleation events.
To test this idea experimentally, we performed kinetic experiments
where a solution of 5% (w/w) of preformed seed fibrils was added to
solutions ofmonomeric Ab(M1-42) (Fig. 1D); under these conditions,
primary and secondary nucleation events are negligible, and fibril
elongation is the major contributor to the increase in fibril mass (30).
By increasing the concentration of clusterin, we observed a progressive
reduction in the rate of aggregation, supporting the conclusion that
the molecular chaperone inhibits this specific microscopic process.
In addition, the elongation rate constants calculated from simulations
of the experimental data under seeded conditions are in excellent
agreement with the values determined under unseeded conditions,
confirming the robustness of our analysis (Fig. 1E).
Previous kinetic analysis of Ab(M1-42) profiles indicates that
monomeric species participate directly in elongation and primary/
secondary nucleation rates (10). In particular, the elongation reaction
involves the addition of monomers to fibril ends and smaller propa-
gons, such as oligomers and other prefibrillar species, and therefore,
the inhibition effect of clusterin could result from its interactions
with either of the three species (9, 31). Substantial binding of the mo-
lecular chaperone to monomeric Ab(M1-42) would, however, also
affect primary and secondary nucleation reactions, because these
processes also depend on the concentration of monomers. As the ki-Scheidt et al., Sci. Adv. 2019;5 : eaau3112 17 April 2019netic analysis reveals that clusterin inhibits only the elongation rate,
we can conclude that it interacts preferentially with the fibril ends
and all species capable of elongation. The fact that inhibition is ob-
served at very low substoichiometric ratios is completely associated
with the interaction of clusterin with the ends of fibrils or prefibrillar
species, as interactions with monomeric Ab(M1-42) would require a
much higher stoichiometric concentration of clusterin to affect the
rates to such a substantial extent.
To interpret the kinetic effects in a more quantitative manner,
we compared the experimental data with the prediction of a kinetic
model that considers explicitly binary interactions between clusterin
and the ends of Ab(M1-42) fibrils (see Materials and Methods). The
theoretical predictions account well for the concentration depen-
dence of the inhibition at 37°C by using the fitting parameters
kon,37°C = 4 × 10
5 M−1 s−1 and koff,37°C = 1 × 10
− 3 s−1 (Fig. 1F),
corresponding to KD,37°C = 2.5 nM. From an analysis of the depen-
dence of the apparent elongation rate constant on the molecular
chaperone concentration (Fig. 1E) using a simplified kinetic model,
in which the binding reaction process is assumed to be under equi-
librium conditions (see Materials and Methods), we obtain a similar
value of KD,37°C = 8 nM. We repeated the experiment at a tempera-
ture of 21°C and obtained a value of KD,21°C = 1 nM (fig. S2), indicat-
ing that the binding is exothermic. The exergonic binding and the
high interaction affinity are consistent with the fact that clusterin
interacts with Ab(M1-42) fibrils in an adenosine 5′-triphosphate
(ATP)–independent manner (32).
The interactions between clusterin and fibrils of Ab(M1-42) were
probed in additional kinetic experiments. To this effect, Ab(M1-42)
fibrils were generated in the presence or absence of clusterin and
then added to freshly prepared monomer solutions in the presence
or absence of clusterin (fig. S3). Even in the absence of clusterin in
the monomer solution (fig. S3B), the preformed fibrils that had been
produced in the presence of clusterin accelerated aggregation to a
smaller extent than did fibrils produced in the absence of the chap-
erone (fig. S3A). Application of the kinetic analysis reveals a reduc-
tion of ca. 40% in the elongation rate in this latter case (fig. S3B),
indicating that a substantial fraction of the molecular chaperone
must have remained bound to the aggregates during the time course
of the reaction, and immunogold transmission electron microscopy
(TEM) analysis (Fig. 2, B and D) indicates that clusterin is bound to
these Ab(M1-42) fibrils. Furthermore, the ability of fibril ends to
grow was also observed to be substantially reduced when preformed
aggregates generated in the absence of the chaperone were added to a
mixture of clusterin and monomeric Ab(M1-42) (fig. S3C), demon-
strating the ability of clusterin to inhibit even ongoing reactions. By
contrast, in this set of experiments, the fibrils that had not been ex-
posed to the molecular chaperone at any stage maintained their full
ability to elongate (fig. S3A).
Quantification of interactions between clusterin and
Ab(M1-42) fibrils by microfluidic diffusional sizing
Together, the kinetic data described in the previous sections sug-
gest that clusterin is highly effective at inhibiting the aggregation
of Ab(M1-42) at low substoichiometric ratios by specifically reducing
the rate of elongation, and provide strong evidence that this process is
mediated by the noncovalent association of clusterin with Ab(M1-42)
fibril ends and prefibrillar species. The interactions between the mo-
lecular chaperone and the fibrils, therefore, represent the key molec-
ular process underlying the inhibition of fibril elongation.2 of 9
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is provided by immunogold (TEM) (Fig. 2) whenwe specifically probe
for the presence of clusterin on the Ab(M1-42) fibrils; under a variety
of conditions, which implement stringent washing steps and the use
of bovine serum albumin (BSA) incubation to reduce nonspecific
binding, it is apparent that clusterin binds to the Ab(M1-42) fibrils.
Although it appears that gold labeling is occurringmainly at the fibril
ends, it is not possible to conclude that there are no interactions of
clusterinwith the surfaces of the fibrils. The quantity of bound clusterin
can be seen to be increased when the molecular chaperone was incu-
bated with fibrils that were exposed to mechanical breakage by sonica-Scheidt et al., Sci. Adv. 2019;5 : eaau3112 17 April 2019tion. These shorter fibrils have a larger number of ends at constant
surface area compared to the unsonicated fibrils (Fig. 2D). Although
this imaging analysis cannot be carried out rigorously in a quantitative
manner, this result suggests that the molecular chaperone interacts
preferentially with fibril ends, in agreement with the conclusion from
the specific inhibition of the elongation rate observed in this study by
the kinetic analysis and discussed earlier.
To characterize the interactions between clusterin and Ab(M1-42)
fibrils in a more quantitative manner, we made use of microfluidic
diffusional sizing that has recently been developed to measure the
interactions between biomolecules directly in solution under native0 5 10 150 5 10 150 5 10 15
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Fig. 1. Analysis of the effects of clusterin on the aggregation kinetics of Ab(M1-42). (A to C) Kinetic reaction profiles for the aggregation of 4 mM Ab(M1-42)
solutions are shown in each panel from left (blue) to right (green) in the absence and presence of 7.5, 37, 75, and 135 nM clusterin, with each color representing
repetitions at the same concentration. The integrated rate law for Ab(M1-42) aggregation in the absence of clusterin using the rate constants, previously determined by
a least-squares error function, is shown as a dark blue line in each case (10). Predicted profiles of the specific inhibition processes of (A) primary nucleation, (B) fibril
elongation, and (C) secondary nucleation generated by clusterin are shown as continuous lines. Note the characteristic differences in the changes in the shape of the
reaction profiles in each case. The prediction for the case where the molecular chaperone suppresses only elongation events matches closely the experimental data in
the presence of different concentrations of clusterin. (D) Kinetic reaction profiles for the aggregation reaction of a 2 mM Ab(M1-42) solution seeded with 100 nM preformed
fibrils in the absence and presence of 7.5, 37, 75, and 135 nM clusterin. The lines represent the integrated rate laws for Ab(M1-42) aggregation, where the elongation rate has
been selectively reduced. The apparent elongation reaction rates as a function of the molecular chaperone concentration evaluated from the fitting in (B) and (D) are reported
in (E) for both unseeded and seeded reactions. The continuous line in (E) represents a simplified correlation between the elongation rate and the binding affinity constant (see
Materials and Methods), from which KD,37°C = 8 nM is determined. (F) Comparison between the experimental data reported in (B) and theoretical predictions of the reaction
profiles calculated from a kinetic model, which considers the association and dissociation rate constants in the reaction scheme with KD,37°C = 2.5 nM. (G and H) Schematic
diagrams showing the molecular pathways involved in Ab(M1-42) aggregation (G) and the mechanism by which clusterin perturbs the aggregation process (H).3 of 9
SC I ENCE ADVANCES | R E S EARCH ART I C L Econditions (33, 34). Briefly, the principle of this technique consists of
acquiring, in both space and time, the longitudinal diffusion profiles
ofmolecules in a solution flowing in amicrofluidic channel (Fig. 3A).
The diffusion profiles acquired in these experiments can then be ana-
lyzed by considering advection-diffusion processes to extract the
distribution of diffusion coefficients and therefore the distributions
of the hydrodynamic radii of the individual species present in solu-
tion (33).With this technique, interactions betweenmacromolecules
can be detected by monitoring the increase in size associated with
these events.
We therefore monitored the binding of clusterin to Ab(M1-42)
fibrils by measuring the diffusion of clusterin labeled with the fluores-
cent dye Alexa Fluor 488 in the absence and presence of Ab(M1-42)
fibrils (Fig. 3C and fig. S4). Clusterin bound to a fibril will diffuse sub-
stantially slower than the unbound species because of the much
greater size of the fibrils related to the molecular chaperones and
hence exhibit a distinct diffusion profile (Fig. 3C). The size distributions
extracted from the diffusion profiles are shown in Fig. 3D; in the absence
of Ab(M1-42) fibrils, clusterin exhibits a monomodal distribution
centered at a hydrodynamic radius of about 8 nm. In the presence of
the fibrils, however, a bimodal distribution is observed, with a popula-
tion similar to the hydrodynamic radius of themonomodal distribution
corresponding to unboundmolecular chaperone, and a peak in the larger
size range corresponding to complexes formedby clusterin and amyloid
fibrils. The integral of the area under the two subpopulations is propor-
tional to the concentration of free and bound clusterin. From the titra-Scheidt et al., Sci. Adv. 2019;5 : eaau3112 17 April 2019tion curve, obtained by performing experiments at different clusterin
concentrations between 0 and 4.5 mM with a fibril concentration of
17.5 mM (Fig. 3E), we obtained a KD,21°C value of 670 nM. This value
is two orders ofmagnitude larger than theKD estimated from the kinetic
analysis at the same temperature (KD,21°C = 1 nM); the difference may
arise from the specific types of information provided by the two
approaches. As can be seen by TEM images, clusterin binds both to
the surfaces and to the ends of the fibrils, and the microfluidic diffusion
technique detects the total quantity of bound clusterin resulting from
these two interactions. By contrast, the kinetic analysis is sensitive only
to interactions with the growing fibril ends and the smaller propagons,
which determine the modulation of the elongation rate, and therefore
reports a higher affinity. These findings indicate that clusterin is capable
of suppressing Ab(M1-42) aggregation under physiological concentra-
tion, but higher concentrations of molecular chaperone are needed to
reduce substantially the effect of toxic species, in agreement with pre-
viously reported results (35, 36). As a control experiment, we studied
the interaction and the inhibition effects of clusterin when a non-
chaperone protein, BSA, is added into the system (Fig. 3E and fig. S5)
and detected no effect on binding.
Modulation of Ab(M1-42) aggregation by Brichos reveals
that the reactive sites of secondary nucleation and
elongation are distinct
Although there is evidence from the immunogold labeling and the
diffusion experiments that clusterin may be able to bind along the
surface of the fibrils, as well as to their ends, the kinetic experiments
show that clusterin does not inhibit detectable surface-catalyzed
secondary nucleation. By contrast, a molecular chaperone belonging
to the Brichos family (proSP-C Brichos) has been found to inhibit the
secondary nucleation rate associated with Ab(M1-42) aggregation
but not the rate of elongation (11). This observation suggests that in-
hibition of secondary nucleation processes requires specific interac-
tions with defined reactive sites on the fibrils rather than nonspecific
binding along their surfaces. It also suggests that the sites involved in
the nucleation and elongation processes are likely to be distinct. To
address this question, as well as to conclude whether or not the effect
of the twomolecular chaperones is additive, we added 18 nM clusterin
and 2 mM proSP-C Brichos, both individually and together, to a solu-
tion of 2.5 mM Ab(M1-42) and monitored the aggregation over time.
We observed a larger inhibition of the aggregation kinetics when the
twomolecular chaperones are present together in the solution (Fig. 4).
Moreover, the kinetic profiles can be described very closely by simu-
lation using the rate constants determined in the experiments where
the two molecular chaperones were added individually. In particular,
the results show that inhibition by proSP-C Brichos on the secondary
nucleation rate is essentially the same in the presence or absence of
clusterin, and reduction of the elongation rate constant is not detec-
tably affected by the presence of proSP-C Brichos (corresponding to
the values reported in Fig. 1E).
The finding that the inhibition effects of the two molecular chap-
erones studied here are additive is extremely interesting and has a
number of important implications: First, it indicates that the sites
on the amyloid fibrils involved with the two different microscopic
processes of elongation and secondary nucleation pathways are dis-
tinct, a result consistent with a recent study showing the develop-
ment of antibodies able to target specifically distinct steps (15, 37).
Moreover, biologically relevant molecular chaperones can interact with
these different sites in an additive noncooperative way. ExperimentalA B
DC
2o antibody only 1o + 2o antibodies
Fig. 2. Analysis of clusterin interactions with Ab(M1-42) fibrils using immuno-
gold TEM. Ab(M1-42) fibrils formed under quiescent condition imaged as is
(A and B) and after sonication (C and D) were incubated with BSA and clusterin
and stringently washed. Incubation with an anti-mouse secondary antibody
conjugated to a gold particle showed no nonspecific labeling (A and C),
whereas incubation with an anti-clusterin monoclonal antibody followed by
an anti-mouse secondary antibody conjugated to a gold particle shows the
presence of clusterin interacting with the Ab(M1-42) fibrils (black dots). Scale
bars, 100 nm.4 of 9
SC I ENCE ADVANCES | R E S EARCH ART I C L Erepetitions (fig. S7) at different inhibitor concentrations confirm
the additive and noncooperative inhibition effect of the two indi-
vidual chaperones.DISCUSSION AND CONCLUSION
Increasing evidence indicates that the aggregation networks leading
to the formation of amyloid fibrils are composed of a series of distinct
microscopic reactions (9, 38, 39). For Ab(M1-42), secondary nuclea-
tion under the in vitro conditions studied has emerged as the most
important source of toxic oligomeric species (10, 40). Understanding
the molecular details of this process, which is now feasible throughScheidt et al., Sci. Adv. 2019;5 : eaau3112 17 April 2019the development of chemical kinetic analysis, is therefore of vital
importance for understanding the fundamental processes that are
likely to be involved in AD. In this work, we have built on the ability
of this kinetic platform to identify the different microscopic mecha-
nisms of the inhibitory effects of twomolecular chaperones on amyloid
formation by Ab(M1-42). We have observed that clusterin induces a
similar reduction of the parameters k+k2 and k+kn, in agreement with
previous findings (26). Moreover, our analysis of seeded aggregation
profiles demonstrates that, for our recombinant peptide, this obser-
vation can be explained at the microscopic level by a reduction of the
elongation rate constant and not by an equal reduction of primary
and secondary nucleation rates. In particular, we have shown that theN
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implies a selective inhibition of two different microscopic reactions,
namely, elongation and surface-induced secondary nucleation. This
result suggests that the natural protectivemechanisms that have evolved
tomaintain the protein homoeostasis network are highly sophisticated
and work together to suppress different steps in the series of events
that give rise to protein aggregation and amyloid formation. Specific
inhibition of elongation reactions alonewould inhibit the formation of
surface available for secondary nucleation but could lead to an accu-
mulation of soluble intermediates and an increase in toxicity. For a
complete inhibition of the aggregation process, therefore, additional
interactions with the surfaces of the fibrils are required to suppress
secondary nucleation events, a finding in good agreement with pre-
vious reports (36). Future developments of the analysis described in
this work may also clarify the behavior observed in the more complex
environment of in vivo systems, for example, where overexpression
of clusterin has been shown to accelerate amyloid deposition in mice
but to decrease the risk of AD in humans (41–43). More generally,
understanding how the aggregation process is altered by specific mo-
lecules is crucial to evaluate the consequences for the generation of
potential toxic oligomeric species. These molecular details are par-
ticularly relevant in the context of the rational design of drug mole-
cules that could, potentially in combination, target multiple specific
aggregation steps in a selective manner.Scheidt et al., Sci. Adv. 2019;5 : eaau3112 17 April 2019MATERIALS AND METHODS
Materials
The expression and purification procedure for the peptide Ab(M1-42)
(MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV-
VIA) and the molecular chaperones clusterin and proSP-C Brichos
were carried out as described in previous papers (44–47). In short,
Ab(M1-42) inclusion bodies were extracted from Escherichia coli cells
by sonication and dissolved in 8M urea. Further purification was per-
formed by ion exchange in batch mode on DEAE cellulose resin with
additional lyophilization and gel filtration on a 3.4 cm × 200 cm gel-
filtration column at 4°C (44).
To obtain the proSP-C Brichos domain, E. coli cells were lysed by
lysozyme (1mg/ml) for 30min and incubated with deoxyribonuclease
and 2mMMgCl2 for another 30min on ice. The centrifuged cell pellet
was dissolved in 2 M urea in 20 mM tris and 0.1 M NaCl (pH 8) and
sonicated for another 5 min. After another centrifugation step, the
supernatant was filtered through a 5-mm filter and purified with a
2.5-ml nickel-agarose column. The thioredoxin and His6 tag were
removed by adding thrombin for 16 hours at 4°C, followed by another
run through a nickel column. The protein was further purified by ion
exchange chromatography (45, 46).
Clusterin was extracted from human blood plasma obtained from
Wollongong Hospital (Wollongong, New South Wales, Australia).
Complete protease inhibitor was added, and the mixture was filtered
through (i) a GF/C glass fiber filter and then (ii) a 0.45-mm cellulose
nitrate filter. The filtrate was further purified on a 5-ml G7 anti-CLU
monoclonal antibody column. After severe washing steps, the specif-
ically bound material was eluted using 2 M GdnHCl in phosphate-
buffered saline (PBS). The fraction was dialyzed against 20 mMMES
(pH6.0) and loaded on a 1-mlHiTrap SPXL cation exchange column,
collecting the flow through. Last, the pure protein was obtained by size
exclusion chromatography on a Superose 6 10/300 column (47). For
the microfluidic experiments, clusterin was covalently labeled with
Alexa Fluor 488 N-hydroxysuccinimide ester (Thermo Fisher Scien-
tific, Waltham, USA). To achieve this, the protein (2 mg/ml) was in-
cubated with a 10-fold molar excess of the fluorophore (added from a
10mM stock in dimethyl sulfoxide) [1 hour, room temperature (RT)].
Unconjugated dye was removed by buffer exchange into PBS using a
PD-10 column (GEHealthcare, Chicago, USA). The final protein con-
centration and labeling efficiencywasmeasured according to theman-
ufacturer’s instructions. We carried out kinetic experiments to show
that the labeling with the Alexa dye, required for the fluorescence de-
tection, does not modify the inhibition and the binding properties of
clusterin (fig. S6). BSA, obtained fromSigma-Aldrich (St. Louis, USA),
was used. All aggregation assays and binding reactions were carried
out in 20 mM sodium phosphate buffer at pH 8.0. All chemicals were
of analytical grade and purchased from Sigma-Aldrich, unless other-
wise stated.
Kinetic aggregation assay
Aggregation reactions in the presence and absence of clusterin and
proSP-C Brichos were followed by recording ThT fluorescence emis-
sion at 480 nm after excitation at 440 nm. Samples (100 ml) were
incubated in the Corning (Corning, USA) 96-Well (COSTAR) Half-
Area Black with Clear Flat Bottom Polystyrene NBS Microplate, and
measurements were recorded in a FLUOstar OPTIMA plate reader
(BMG Labtech, Ortenberg, Germany) at 21° or 37°C under quiescent
conditions (10). For seeded reactions, fibrils were freshly prepared
before each experiment and mixed with freshly purified monomeric0 5 10
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Fig. 4. Brichos and clusterin exhibit modular and additive behavior of their
specific inhibition processes. (A) Kinetic profiles of 3 mM Ab(M1-42) solutions in
20 mM sodium phosphate buffer at pH 8.0 in the absence and presence of 18 nM
clusterin and 2 mM proSP-C Brichos added either individually or together as indi-
cated at 37°C. (B) The additivity of the inhibition effects reveals that the sites as-
sociated with the two different microscopic steps of elongation and secondary
nucleation are distinct. Continuous lines represent model simulations where either
the elongation rate constant (green line), secondary nucleation rate constant (red
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terin,monomeric, and fibrillarAb(M1-42) for the different experiments
are reported in themain text and SupplementaryMaterials as well as in
the captions of the figures. The concentration of ThT was 20 mM in
all experiments that we carried out at 37°C, unless otherwise stated.
Kinetic analysis and simulations
The aggregation profiles in the absence and presence of different
concentrations of molecular chaperones were simulated individually
according to the following equation
MðtÞ
Mð∞Þ ¼ 1
Bþ þ Cþ
Bþ þ Cþekt
B þ Cþekt
B þ Cþ
  k2∞
k~k∞
ek∞t ð1Þ
where the kinetic parameters B±, C±, k, k∞, and ~k∞ are functions of
the mass and number concentrations of seeds as well as of the two
combinations of the microscopic rate constants k+k2 and knk2, where
kn, k+, and k2 are the rate constants of primary nucleation, elonga-
tion, and secondary nucleation, respectively (38, 39).
The microscopic rate constants in the absence of the molecular
chaperones were considered equal to the values estimated in previous
work (10). The rate constants in the presence of different concen-
trations of clusterin were determined by fitting the individual reac-
tion profiles by minimizing a least-squares error function defined as
y ¼ ∑texpi¼1ðMsimðtiÞ MexpðtiÞÞ2 , where Msim(ti) and Mexp(ti) are
the simulated and experimental total fibril mass fractions at time
ti, respectively. In the simulations shown in Fig. 1, kn, k+, and k2 were
varied individually, but in the simulations shown in the other
figures, only k+ has been modified.
The experimental data in the absence and presence of clusterin
were described by a second kinetic model, which considers binary
interactions between clusterin and fibril ends. The detailed descrip-
tionof the corresponding equations can be found in (18). In thismodel,
the rate constants kn, k+, and k2 were assumed to be equal to the values
estimated in the absence of the chaperone and considered to be in-
dependent of the concentration of clusterin, the effect of which is in-
cluded in the association and dissociation rates. The association and
dissociation rate constants were estimated by the global analysis of
the reaction profiles at different concentrations of clusterin by mini-
mizing a least-squares error function similar to that described above
(18). The simulation reported in Fig. 1E is based on a simplified ex-
pression, which can be derived from this second kinetic model, and
relates the apparent elongation rate constant to the total concentration
of chaperone ðCToti Þ and the equilibrium constant of the association
reaction (18)
kappþ =kþ ¼
2þ KeqEndCToti
2þ 2KeqEndCToti þ 2 KeqEndCToti
 2 ð2Þ
In this study, we report the dissociation constant KD = 1/KeqEnd.
Immunogold-labeling TEM
Ab(M1-42) fibrils [1.5mMAb(M1-42)monomer equivalents] were in-
cubated with BSA (1 mM; New England Biolabs) in 20 mM phosphate
buffer (pH 8.0) (10 min, RT). Clusterin (0.15 mM) was added to the
solution and further incubated (10 min, RT). The fibril sample wasScheidt et al., Sci. Adv. 2019;5 : eaau3112 17 April 2019centrifuged (15,000 rpm, 20 min, 4°C), and the supernatant was re-
moved. The pellet was resuspended in PBS containing 0.01% (v/v)
Triton and 0.01% (v/v) Tween 20 (15 ml), and then the sample was
centrifuged (15,000 rpm, 20 min, 4°C). The pellet was resuspended in
PBS (10 ml). For the sonicated samples, Ab(M1-42) fibrils (1.5 mM)were
sonicated using a probe sonicator (Bandelin, SONOPULS HD 2070)
for 1 min with 10% maximum power and 30% cycles before incuba-
tion with BSA and clusterin. The prepared fibril samples (5 ml) were
applied to a carbon support film, 400 mesh, 3-mm nickel grid (EM
Resolutions Ltd., Saffron Walden, UK) and incubated (5 min, RT).
The grid was blocked with BSA (1 mg/ml) in PBS for 15 min and in-
cubated with 1:100 G7 mouse anti-human clusterin monoclonal anti-
body [stock solution (2 mg/ml)] in PBS for 30 min. For the secondary
antibody–only negative controls, samples were incubated with PBS
only at this step. The grid was washed (three times for 5 min), first,
in PBS/0.01% Triton/0.01% Tween 20 and then twice with PBS only,
followed by incubation with 1:500 gold-labeled anti-mouse secondary
antibody (BBI Solutions, Cardiff, UK) in PBS for 30min. Last, the grid
was washed three times as described above, twice with water, and then
incubated for 2 min with 2% uranyl acetate (w/v). To remove excess
uranyl acetate, the grid was washed twice with water and dried com-
pletely before imaging. The fibrils were imaged on a FEI Tecnai G2
TEM(CambridgeAdvanced ImagingCentre, University of Cambridge,
UK). Images were analyzed using the SIS MegaView II Image Capture
System (Olympus, Tokyo, Japan).
Preparation of samples for binding measurements
Ab(M1-42) fibrils were generated by incubating 17 mM monomeric
Ab(M1-42) in 20 mM sodium phosphate buffer at pH 8.0 in a 96-well
plate in a FLUOstar OPTIMA plate reader (BMG Labtech) at 37°C
with double orbital rotation (400 rpm). Aggregation wasmonitored
by following the increase in the fluorescence emission of a similar
sample implemented with 20 mM ThT dye initiated upon its bind-
ing to amyloid fibrils. After completion of the aggregation reaction,
the fibrils were collected, supplemented with Alexa Fluor 488–labeled
clusterin in the concentration range between 0 and 4.5 mM, and in-
cubated for at least 2 days at 21°C to ensure that equilibrium was
obtained. Diffusion sizing measurements were then performed at
21°C, as described below. In a second set of experiments, three more
points were evaluated with the addition of BSA (at the same con-
centration as used in the clusterin experiments, i.e., 0.8, 2, and 4.5 mM)
added to a mixture of clusterin and fibrils, as described above, to
examine the specificity of the binding with 17.5 mM Ab(M1-42)
fibrils. The samples were again analyzed by microfluidic diffusion
methods.
Microfluidic diffusional sizing
The fabrication and the operation of the microfluidic diffusion de-
vice used in the present studies have been described in previous papers
(33, 48). Briefly, the microfluidic chips were fabricated by using stan-
dard soft lithography. The sample to be analyzed and the buffer were
introduced into the system through reservoirs connected to the inlets,
and the flow rate in the channel was controlled by applying a negative
pressure at the outlet by a syringepump(CETONIneMESYS,Korbussen,
Germany) at typical flow rates in the range from 60 to 90 ml/hour. Lat-
eral diffusion profiles were recorded at 12 different positions (3.5, 5.3,
8.6, 10.3, 18.6, 20.3, 28.6, 30.4, 58.7, 60.4, 88.7, and 90.5 mm) by stan-
dard epifluorescence microscopy using a cooled charge-coupled device
camera (Photometrics Evolve 512, Tucson, USA). The diffusion profiles7 of 9
SC I ENCE ADVANCES | R E S EARCH ART I C L Ewere fitted to model simulations on the basis of advection-diffusion
equations assuming a bimodalGaussian distribution (48). From the area
under the curves of the two Gaussian populations, the concentrations
of the bound and free molecular chaperones were evaluated. The dis-
sociation constantKDwas calculated by direct nonlinear regression on
the basis of the Langmuir binding isotherm (49, 50)
½clusterinbound ¼ ½clusterinfree⋅½MKD þ ½clusterinfree ð3Þ
where M is the total concentration of binding sites available on the
Ab(M1-42) fibrils, representing themaximumconcentration of bound
molecular chaperone, while [clusterinbound] and [clusterinfree] are the
concentrations of bound and free molecular chaperone, respectively.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/4/eaau3112/DC1
Fig. S1. Analysis of the effects of clusterin on the aggregation kinetics of Ab(M1-42) at 37°C.
Fig. S2. Analysis of the effects of clusterin on the aggregation kinetics of Ab(M1-42) at 21°C.
Fig. S3. Seeding experiments of Ab(M1-42) in the presence and absence of clusterin.
Fig. S4. Diffusion profiles of specific samples at 12 different positions in a microfluidic device.
Fig. S5. Analysis of interfering effects of transient proteins on clusterin inhibition activity.
Fig. S6. Effects of the fluorescent label of clusterin on the inhibition process on Ab(M1-42)
aggregation.
Fig. S7. Kinetic analysis on the aggregation kinetics of Ab(M1-42) in the presence of Brichos
and clusterin separately and combined.REFERENCES AND NOTES
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